Yoshinobu Iwasaki
Overview
Explore the profile of Yoshinobu Iwasaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
233
Citations
1984
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takahashi H, Iwasaki Y, Watanabe T, Ichinose N, Oda T
BMC Infect Dis
. 2022 Mar;
22(1):277.
PMID: 35317729
Background: Although the RECOVERY trial showed that dexamethasone was efficacious for the treatment of coronavirus disease 2019 (COVID-19), its impact on the risk of pulmonary embolism (PE) and other serious...
2.
Kurozumi A, Takahashi H, Watanabe T, Iwasaki Y
Thorac Cancer
. 2021 Mar;
12(10):1625-1628.
PMID: 33783978
We report the cases of two patients with secondary hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors, who were diagnosed using the recently developed HScore. The first patient presented with fever,...
3.
Fujii K, Takahashi H, Hayakawa N, Iwasaki Y
Respirol Case Rep
. 2021 Jan;
9(2):e00708.
PMID: 33437491
See related Letter.
4.
Fujii K, Takahashi H, Hayakawa N, Iwasaki Y
Respirol Case Rep
. 2020 Oct;
8(8):e00665.
PMID: 33005423
We report a patient with idiopathic hypereosinophilic syndrome (I-HES) who achieved remission with benralizumab after relapsing on mepolizumab. An 83-year-old man was admitted to Showa General Hospital after presenting with...
5.
Takahashi H, Iwasaki Y, Watanabe T, Ichinose N, Okada Y, Oiwa A, et al.
Int J Infect Dis
. 2020 Aug;
100:283-285.
PMID: 32829044
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is rising globally. However, clinically effective antiviral treatments are not established. Favipiravir may prevent pneumonia and acute respiratory distress syndrome aggravation....
6.
Takahashi H, Koiwa T, Fujita A, Suzuki T, Tagashira A, Iwasaki Y
Respir Med Case Rep
. 2020 Jun;
30:101097.
PMID: 32489850
Treatments using immune checkpoint inhibitors such as pembrolizumab lead to immune mediated adverse effects including hemophagocytic lymphohistiocytosis (HLH). Herein, we present a case where HLH developed after pembrolizumab administration, which...
7.
Chihara Y, Yoshimura A, Date K, Takemura Y, Tamiya N, Kohno Y, et al.
Oncologist
. 2019 May;
24(8):1033-e617.
PMID: 31040252
Lessons Learned: In terms of efficacy and safety, good results were obtained with S-1 and paclitaxel (PTX) combination therapy.The findings suggest that S-1 and PTX combination therapy is a feasible...
8.
Yoshimura A, Chihara Y, Date K, Tamiya N, Takemura Y, Imabayashi T, et al.
Oncologist
. 2018 Dec;
24(4):459-e131.
PMID: 30578309
Lessons Learned: Coadministration of S-1 and paclitaxel in elderly patients with advanced non-small cell lung cancer showed favorable efficacy.Coadministration of S-1 and paclitaxel in elderly patients with advanced non-small lung...
9.
Hidaka T, Okuzumi S, Matsuhashi A, Takahashi H, Hata K, Shimizu S, et al.
Intern Med
. 2018 Oct;
58(4):563-568.
PMID: 30333385
Large cell neuroendocrine carcinoma (LCNEC) is a highly malignant cancer originally found in lung in 1991. In extremely rare occasions, primary LCNEC is found in the mediastinum; approximately 40 of...
10.
Chihara Y, Date K, Takemura Y, Tamiya N, Kohno Y, Imabayashi T, et al.
Invest New Drugs
. 2018 Aug;
37(2):291-296.
PMID: 30121935
This phase I study was aimed at determining the maximum tolerated dose (MTD) and recommended dose (RD) for oral S-1 plus paclitaxel combination therapy in elderly patients with non-small cell...